protocol. A suspicious mpMRI lesion was defined as having a Prostate Imaging Reporting and Data System (PI-RADS) score 4, whereas clinically significant cancer was defined as cancer with Gleason grade 3+4. Descriptive statistics and two-way t-tests were performed with STATAâ 14.
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RESULTS: Of 355 patients, 49.3% (175/355) had a suspicious mpMRI lesion and 47.9% (170/355) of the cohort had significant cancer on biopsy overall. There was moderate sensitivity (67.1%), negative predictive value (71.3%), specificity (69.7%) and positive predictive value (60.9%) for the mpMRI detection of significant cancer in the same or neighbouring location at biopsy. Of the 56 patients with significant cancer but non-suspicious mpMRI (PI-RADS <4), 66.1% (37/56) were Gleason 3+4 and 32.1% (18/56) were matched to a PI-RADS 3 lesion. For Gleason grade 4+4 cancers, 90.4% (47/52) had a corresponding mpMRI lesion with PI-RADS score 4. Examining all patients with significant cancer at biopsy matching to a suspicious mpMRI lesion, 84.2% (96/114) were the highest Gleason grade found on biopsy.
The mean size of suspicious mpMRI lesions with significant cancer on biopsy was significantly larger than those with Gleason 3+3 cancer or no cancer at biopsy (16.7 mm vs.13.9 mm respectively; p¼0.03).
CONCLUSIONS: When precisely mapping the location of mpMRI lesions to positive prostate biopsy cores for significant cancer, a moderate sensitivity and positive predictive value was found suggesting that concomitant systematic biopsy cannot be abandoned. PI-RADS 4 lesions had excellent prediction of high-grade cancers at biopsy. Larger mpMRI lesions may yield more clinically significant cancers on biopsy. 
MP38-15 DETECTION AND CHARACTERIZATION OF DISSEMINATED TUMOR CELLS FROM THE BONE MARROW IN LOCALIZED PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY
Stephanie Glavaris*, Emma van der Toom, Michael Gorin, James Verdone, Changxue Lu, Jun Luo, Kenneth Pienta, Heather Chalfin, Baltimore, MD INTRODUCTION AND OBJECTIVES: Disseminated tumor cells (DTC) are prostate cancer cells that escape the primary lesion and enter the bone marrow (BM) niche, representing a first step towards conventionally detectable metastasis. It is unknown how frequently this occurs in clinically localized prostate cancer. We detected and characterized these cells by measuring gene expression of prostate-specific markers from BM samples taken at the time of radical prostatectomy (RP).
METHODS: 5 mL of BM were harvested at RP for 36 clinically localized patients. A whole cell extract was assayed with the AdnaTest ProstateCancer Select kit (Qiagen). Reverse transcription (SensiScript RT kit, Qiagen) and real-time qPCR quantified expression of RPL13A (control, ribosomal protein), EPCAM (epithelial), NKX3.1 and HOXB13 (prostate-specific), and AR-FL (androgen receptor full length). Prostate markers known to be less sensitive or specific were also assayed in a subset of patients (TMPRSS2-ERG, AR-V7, PSA, and PSMA). DTC detection was defined as prostate-specific marker expression in the BM. Quality control was performed with Sanger sequencing. The associations of PSA and Gleason score (GS) with DTC detection were evaluated with the Mann-Whitney U Test and Fisher 0 s exact test respectively. RESULTS: DTCs were detected via NKX3.1 expression in 30/ 36 patients (83%). HOXB13, AR-V7, and TMPRSS2-ERG were not detected in any sample. 100% of patients were EPCAM+, consistent with the known non-specific expression of EPCAM in the BM. AR-FL was also non-specifically expressed in 67% of NKX3.1+ and 83% of NKX3.1-patients. There was a trend toward DTC detection associating with higher PSA and GS, with 100% of NKX3.1-patients having low-risk PSA<10, and only one with primary GS >3 (17%, 1/6). Conversely 47% (14/30) of NKX3.1+ patients had primary GS4, and 27% (8/30) had PSA>10. Yet, this was not statistically significant (GS p¼0.367, PSA p¼0.302) , and DTCs were detected across all Gleason scores. CONCLUSIONS: DTCs were detected based on NKX3.1 positivity in a large portion of clinically localized prostate cancer patients at all Gleason scores. Ongoing investigation with healthy patient BM will clarify whether NKX3.1 is truly prostate-specific, and if its expression associates with clinico-pathologic outcomes.
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MP38-16 COMBINING 68GA-PSMA-PET AND MULTIPARAMETRIC MRI: ENHANCING THE ABILITY TO DETECT INTRAPROSTATIC TUMOUR LESIONS AND PATIENTS ELIGIBLE FOR FOCAL TREATMENT ?
INTRODUCTION AND OBJECTIVES: Functional 68Ga-labelled PSMA or morphologic mpMRI-imaging detects intraprostatic prostate cancer (PCa) foci. To assess the diagnostic performance of 68Ga-PSMA-PET-CT or mpMRI alone and their combination for characterising side specific intraprostatic PCa cancer lesions, when performed in a sequential setting.
METHODS: Overall, 30 patients with biopsy proven prostate cancer received a 68Ga-PSMA-PET-CT and mpMRI imaging prior radical prostatectomy (RP). Preoperative intraprostatic findings of both different modalities and their combination were compared with histological work up after RP. Lesions were classified positive with mpMRI (Likert scale >3) and PET/CT foci with elevated SUVmax (focus vs. background).
RESULTS: Median PSA was 9.0 ng/ml (IQR 4.2-35.7). MpMRI and PET/CT identified (IQR) 2 (1-2) tumorfoci. Sidespecific sensitivity of mpMRI, PET/CT and the combined imaging approach was 83.3% (95% CI 70.7-92.1%), 79.6% (95%CI 66.5-89.4%) and 94.4% (95%CI 54.5-98.8%). Overall sidespecific specifity was 66.7% (95%CI 22.3-95.7%). Sensitivity per patient was 63.3% (95%CI 46.7-80% mpMRI), 56.7% (95%CI 40.0-73.3% PET/CT) and 83.3% (95%CI 70.0-96.7%) for the combined approach.
CONCLUSIONS: Combining functional 68Ga-PSMA-PET and morphologic mpMRI imaging increases the ability to detect intraprostatic tumour lesions without affecting the specifity. Our data demonstrate, that the sequential approach provides a tailored use of both imaging modalities, which reaches similar diagnostic performances e490 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 
